Blood clot is one of the serious complications in the human body. When blood clots, major arteries or veins are blocked which cease the normal blood flow. The cessation of normal blood flow can implicate hemorrhage and often lead to heart attack and stroke. Thrombolytic therapy is a treatment to dissolve solid blood clots by administrating thrombolytic drugs. The length of the therapy depends upon the type or degree of complications. The treatment may require almost one hour in the case of a heart attack or may need 48 hours in the case of deep vein thrombosis. Brain CT test, electrocardiogram, and electroencephalogram are effective ways to evaluate whether patients are good candidates for thrombolytic therapy. Patients who had undergone recent surgery and blood thinning treatment or with conditions such as pregnancy, trauma, and high blood pressure are not recommended to thrombolytic therapy.
Urokinase, streptokinase, and tissue plasminogen activator (tPA) are basic thrombolytic drugs available in the market for thrombolytic therapy. In 1933, the efficiency of streptokinase as a thrombolytic agent was first stated. Later on, streptokinase was applied to acute myocardial infarction. Unlike streptokinase, urokinase has the ability to catalyze fibrin formation from plasminogen. The growth of the global thrombolytic therapy market is driven by several factors such as aging population, awareness about the adverse effect of thrombosis, rate of diagnosis and treatment, and increase in the incidence of hypertension, kidney diseases, strokes, and other cardiovascular diseases. However, this market is likely to witness hindrances such as strict drug regulatory system and high drug pricing, which, in turn, might restrict the market growth. Nevertheless, new treatment options and technological breakthroughs are anticipated to highlight new avenues for the market growth in the near future.
The global market for thrombolytic therapy has been segmented based on drug type, application, distribution channel, and region. In terms of drug type, the market is categorized into fibrin specific drugs and non-fibrin specific drugs. The fibrin specific drugs segment is further segmented into tissue plasminogen activator, reteplase, tenecteplase, and others. The non-fibrin specific drugs segment is categorized into urokinase, streptokinase, and plasminogen-activating complex.
In terms of application, the global market is classified into acute myocardial infarction, pulmonary embolism, deep vein thrombosis, blocked catheters, acute ischemic strokes, and others. Most of the drugs are administered intravenously, and the doses are recommended on the basis of the patient’s medical history. In terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and e-pharmacies. Increasing number of retail pharmacies, self-medication tendency, and merging of hospital pharmacies are the factors to consider in this market. The thrombolytic drugs are rarely dispensed through the e-pharmacy channel although there is the emergence of e-pharmacy worldwide.
Geographically, the global thrombolytic therapy market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds the largest market share globally, in terms of revenue, owing to high incidence of deep vein thrombosis/pulmonary embolism (1.17 per 1,000 population per year), rise in awareness, high diagnosis and treatment rate, and well-established health care infrastructure. Europe is projected to account for the second largest market share due to high diagnosis and treatment rate, considerable incidences of deep vein thrombosis/pulmonary embolism, and presence of robust health care facilities. Asia Pacific is expected to capture a significant market share during the forecast period because of the presence of large patient pool, particularly, in India and China. Latin America and Middle East & Africa are silent contributors of the global thrombolytic therapy market.
Prominent players operating in the global market for thrombolytic therapy include Eumedica, Genentech (a Roche Group Company), Microbix, Boehringer Mannheim, SEDICO Pharmaceutical, Crinos, Livzon Zhuhai, Medac, Mochida Pharmaceutical, Taj Pharmaceuticals Ltd., NDPharma, and Syner-Medica.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.